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Abstract
Background:  Blood lead concentrations have been associated with increased risk of
cardiovascular, cancer, and all-cause mortality in adults in general population and occupational
cohorts. We aimed to determine the association between blood lead, all cause and cause specific
mortality in elderly, community residing women.
Methods: Prospective cohort study of 533 women aged 65–87 years enrolled in the Study of
Osteoporotic Fractures at 2 US research centers (Baltimore, MD; Monongahela Valley, PA) from
1986–1988. Blood lead concentrations were determined by atomic absorption spectrometry.
Using blood lead concentration categorized as < 8 μg/dL (0.384 μmol/L), and ≥ 8 μg/dL (0.384
μmol/L), we determined the relative risk of mortality from all cause, and cause-specific mortality,
through Cox proportional hazards regression analysis.
Results: Mean blood lead concentration was 5.3 ± 2.3 μg/dL (range 1–21) [0.25 ± 0.11 μmol/L
(range 0.05–1.008)]. After 12.0 ± 3 years of > 95% complete follow-up, 123 (23%) women who died
had slightly higher mean (± SD) blood lead 5.56 (± 3) μg/dL [0.27(± 0.14) μmol/L] than survivors:
5.17(± 2.0) [0.25(± 0.1) μmol/L] (p = 0.09). Women with blood lead concentrations ≥ 8 μg/dL
(0.384 μmol/L), had 59% increased risk of multivariate adjusted all cause mortality (Hazard Ratio
[HR], 1.59; 95% confidence interval [CI], 1.02–2.49) (p = 0.041) especially coronary heart disease
(CHD) mortality (HR = 3.08 [CI], (1.23–7.70)(p = 0.016), compared to women with blood lead
concentrations < 8 μg/dL(< 0.384 μmol/L). There was no association of blood lead with stroke,
cancer, or non cardiovascular deaths.
Conclusion: Women with blood lead concentrations of ≥ 8 μg/dL (0.384 μmol/L), experienced
increased mortality, in particular from CHD as compared to those with lower blood lead
concentrations.
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Background
Lead is a multitargeted toxicant, affecting cardiovascular,
renal and nervous systems, and may contribute to mor-
bidity and mortality through its adverse impacts on these
systems [1,2].
An association between lead and mortality has been
observed in both occupational and community based
cohorts [3]. Results from the second National Health and
Nutrition Examination Survey (NHANES II, 1976–1980)
showed that blood lead concentration was an important
predictor of mortality [4]. Individuals with baseline blood
lead concentrations of 20 to 29 μg/dL [0.96 to 1.39 μmol/
L (To convert μg/dL of blood lead into μmol/L, multiply
by 0.048)] experienced 46% increased all cause mortality,
relative to those with blood lead concentrations less than
10 μg/dL(0.48 μmol/L) [5]. In NHANES III (1988–1994)
an increased risk of death from all causes, cardiovascular
disease, and cancer was associated with much lower blood
lead concentrations of 5–9 μg/dL(0.24–0.43 μmol/L) as
compared to those with < 5.0 μg/dL [6]. Furthermore
Menke et al documented a 25% increased all cause and
55% increased cardiovascular mortality in NHANES III
(1988–1994) at considerably lower blood lead concentra-
tions: > 3.62 μg/dL (0.17 μmol/L) as compared to those
with < 1.94 μg/dL (0.09 μmol/L) [7]. However they did
not observe an association between blood lead and cancer
mortality in this range of exposure.
Environmental exposures to lead have been associated
with hypertension and the incidence of clinical cardiovas-
cular endpoints such as coronary heart disease, stroke,
and peripheral artery disease [8]. Cardiac abnormalities
such as left ventricular hypertrophy [9] and alteration in
cardiac rhythm [10] have also been documented with lead
exposure. Higher blood concentrations have been associ-
ated with cognitive and neuromuscular decline [11-13],
and renal effects [2,14-16] all of which could contribute
to an increased risk of mortality. The effects of blood lead
concentrations on cancer mortality however, are poorly
understood. In the current analysis we prospectively
examined the association of blood lead concentrations
and mortality in a cohort of 533 white women with mean
age of 72.5 (± 4.4) (range: 68–89) years and mean blood
lead concentrations of 5.3 μg/dL (± 2.3 SD) (range: 1–21).
We hypothesized that woman with blood lead concentra-
tions above a threshold will experience higher total and
cause specific mortality.
Methods
Study Population
The Study of Osteoporotic Fractures (SOF) is a longitudi-
nal cohort study that enrolled 9704 white women from
1986 to 1988 using population-based listings in Balti-
more, MD; Minneapolis, MN; Portland, OR; and the
Monongahela Valley near Pittsburgh, PA. To be eligible to
participate, women had to be aged 65 years or older and
ambulatory. The lead ancillary study was conducted in
1990–1991 in 533 white women aged 65–87 years
enrolled in SOF at either the University of Pittsburgh or
University of Maryland clinics. The participants in this
study of blood lead concentrations represent a conven-
ience sample obtained from two of the clinical centers of
the Study of Osteoporotic Fractures.
Initially, we examined the correlates of blood lead and the
association of blood lead concentrations to cognitive
function [17]. Analyses were performed by categorizing
the study participants into three groups corresponding to
the upper and lower 15th percentiles of the distribution of
blood lead. Thus, the three groups were: low [= 3 μg/dl
(0.14 μmol/L), lower 15th percentile; referent; n = 122)];
medium [4–7 μg/dl (0.19–0.34 μmol/L); n = 332]; and
high [= 8 μg/dl (0.38 μmol/L), upper 15th percentile; n =
79]. This categorization was determined a priori [17]. We
found a relationship between blood lead concentration as
low as 8 μg/dL and worse cognitive function as measured
by the part B of Trailmaking Test, but this association was
confined to the rural SOF clinic [17,18]. In a recent anal-
ysis in the same population, we found a significantly
higher risk of falls and fractures in older women at blood
lead concentration ≥ 4 μg/dL (0.19 μmol/L), and faster
rate of bone loss at ≥ 8 μg/dL (0.38 μmol/L), when com-
pared to women with blood lead concentration < 3 μg/dL
(0.14 μmol/L) [19]. In the current paper, we extend the
lead study to mortality outcomes. The protocol and con-
sent forms were approved by the institutional review
boards at the participating institutions. All women pro-
vided written informed consent.
Questionnaire and interview
Each participant completed a baseline questionnaire that
ascertained her education and health behaviors including
smoking, alcohol use, and walking for exercise. They also
were asked about physician diagnosed diabetes, hyperten-
sion (measured blood pressure > 160/90 or thiazide use).
They were asked about current use of estrogen.
Examinations
At the baseline clinic examination, each participant had
her blood pressure measured by manual mercury sphyg-
momanometer. BMD of total hip was measured at the sec-
ond (1988–1990) examination by Dual energy X-ray
absorptiometry (DXA) using Hologic QDR 1000 scanners
(Bedford, Mass). Height and weight were obtained using
a Harpenden stadiometer (Holtain Ltd, Crymych, UK)
and a standard balance beam, respectively, and body mass
index (BMI) was calculated as weight divided by height
squared (Kg/m2).Environmental Health 2009, 8:15 http://www.ehjournal.net/content/8/1/15
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Mortality
The methods of determining deaths in SOF have been
published[20,21]. Briefly, participants were contacted
every 4 months by postcard after visit 2 (1991–92) over
12 (± 3) years of follow-up. These contacts are > 95%
complete. Deaths were confirmed by death certificates.
Hospital discharge summaries were obtained for 41(33%)
of deceased participants. The underlying cause of death
was coded by a clinical epidemiologist using the Interna-
tional Classification of Diseases, Ninth Revision, Clinical Mod-
ification, and categorized as due to cardiovascular disease
(CVD) including all diseases of circulatory system except
those involving veins and lymphatics [ICD-9-CM codes
425, 429.2, 440–444, 428, 401–404, 410–414, 430–438,
and 798.]; Coronary heart disease (CHD) [ICD-9-CM
410–414]; Stroke [ICD-9-CM 430–438]; cancer [ICD-9-
CM codes 140 to 239] and all other deaths.
Blood Lead Measurements
A 5.0 ml sample of whole blood was drawn into Vacu-
tainer tubes (BD Vacutainer Systems, Rutherford, New Jer-
sey). Blood samples were analyzed at the Clinical
Chemistry Laboratory of the University of Maryland, cer-
tified for the analysis of lead in blood by the Occupational
Safety and Health Administration and Centers for Disease
Control and Prevention, and documents a lower limit of
detection for lead of 1 μg/dL. Blood lead concentrations
were determined by graphite furnace atomic absorption
spectrometry (AAS model 5100, HGA with Zeeman Effect
background correction: Perkin Elmer, Norwalk, Connecti-
cut). To determine intralaboratory measurement variabil-
ity in lead concentration and the stability of samples over
1 year, 100 samples (50 from each clinic) were drawn
from randomly selected women during a clinic visit, one
year later. The intraclass correlation coefficient for the
duplicates was 0.88. Mean values of 4.76 μg/dL (range, 1–
13 μg/dL) [0.23(range 0.05–0.62 μmol/L)], and 4.67 μg/
dL (range, 1–12 μg/dL) [0.22 μmol/L (range 0.05–0.58)
were obtained for the first and second determinations,
respectively[17]
Statistical Analysis
Preliminary analyses were performed by categorizing the
study participants into three groups corresponding to the
upper and lower 15th percentiles of the distribution of
blood lead. Thus, the three groups were: low [≤ 3 μg/dl
(0.14 μmol/L), lower 15th percentile; referent; n = 122)];
medium [4–7 μg/dl (0.19–0.34 μmol/L); n = 332]; and
high [≥ 8 μg/dl (0.384 μmol/L), upper 15th percentile; n =
79]. This categorization was determined a priori based on
our previous study of blood lead and cognitive functions
[17]. Analysis suggested that mortality outcome was only
significant at the highest 15th percentile i.e., ≥ 8 μg/dL
(0.384 μmol/L) of blood lead, when compared to the ref-
erent and the medium group, we therefore combined
these two categories into a new reference group with lead
level < 8 ug/dl (0.384 μmol/L). Furthermore, preliminary
analysis by dividing the participants into quintiles, also
suggested that only the top quintile (80th percentile i.e., ≥
8 μg/dL (0.384 μmol/L) of blood lead) showed elevated
risk of death. We therefore dichotomized lead concentra-
tions above and below 8 μg/dL (80th and 85th percentile
was same i.e., ≥ 8 μg/dL(0.384 μmol/L) of blood lead),
thus the two groups were: (< 8 μg/dL, referent, n = 454),
and (≥ 8 μg/dL, n = 79).
We compared baseline characteristics by lead and mortal-
ity status, using chi-square tests for categorical variables
and t-tests for continuous variables. Two-tailed p-values
were used for all tests, at 5% statistical significance. Sepa-
rate models were analyzed for all cause and cause specific
mortality. CVD mortality was categorized into two sub-
groups: deaths due to stroke, and coronary heart disease.
We used Cox proportional hazards regression analysis to
estimate the Hazard Ratio (HR) and 95% confidence
intervals (CI) to determine association between blood
lead concentration and mortality. As done previously in
SOF[22] we assessed variables for inclusion in the models
based on biological plausibility and documented associa-
tion in literature with blood lead [4,5] and mortality [23].
Selected on these criteria, we controlled for the following
variables into all models: age increase per 5 years, clinic,
BMI, education, smoking, alcohol intake, estrogen use,
hypertension, total hip BMD, walking for exercise, and
diabetes.
The proportionality assumptions of the Cox models were
confirmed with Schoenfeld residuals. We plotted cumula-
tive survival in two blood lead concentrations groups over
follow-up period by Kaplan- Meier curves. Data were ana-
lyzed with Stata (edition 9, StataCorp, College Station,
Texas).
Results
The women in lead ancillary study were compared to the
rest of SOF study participants. Lead study cohort was
younger in age from the rest of the SOF participants (Table
1). A lower proportion of women in lead cohort was
hypertensive, or walked for exercise. Proportion of diabet-
ics was higher in the lead study. However, BMI, education,
alcohol use, smoking, use of estrogen, bone density in
total hip were comparable.
Mean blood lead concentration was 5.3 ± 2.3 μg/dL
(range 1–21) [0.25 ± 0.11 μmol/L (range 0.05–1.008)]. A
total of 123 (23%) women died over a mean follow up of
12.0 (± 3.0) years. Women with ≥ 8 μg/dL(0.384 μmol/L),
blood lead concentration had higher alcohol intake, wereEnvironmental Health 2009, 8:15 http://www.ehjournal.net/content/8/1/15
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more likely to smoke, and had 8% lower total hip BMD
(Table 2).
Women who died had 7% higher mean (± SD) blood lead
concentration 5.6 (3) μg/dL, [0.27(± 0.14) μmol/L] than
survivors: 5.17(± 2.0) [0.25(± 0.1) μmol/L] μg/dL (p =
0.09, Table 3). As compared to survivors, women who
died were older, more likely to smoke and to have hyper-
tension. A lower proportion of women who died reported
walking for exercise. Compared to women whose blood
lead concentrations were < 8 μg/dL, (< 0.384 μmol/L) sur-
vival decreased more rapidly in women with blood lead
concentration ≥ 8 μg/dL (≥ 0.384 μmol/L) (Figure 1). Age,
clinic, smoking, hypertension, and total hip BMD were
significantly associated with mortality in women with
blood lead concentration ≥ 8 μg/dL (≥ 0.384 μmol/L)
(Table 4).
Women with baseline blood lead concentration of ≥ 8 μg/
dL (≥ 0.384 μmol/L) had a 73% increased risk of dying.
(Age and clinic adjusted hazard ratio [HR], 1.73; 95%
confidence interval [CI], 1.12–2.68) (p = 0.014) com-
pared to women in blood lead < 8 μg/dL (0.38 μmol/L).
With further adjustment for covariates women with ≥ 8
μg/dL (0.384 μmol/L) still had 59% higher risk of all
cause mortality (HR = 1.59; 1.02–2.49) (p = 0.041), com-
pared to women with < 8 μg/dL (0.38 μmol/L) of blood
lead. Although the multivariate adjusted hazards ratio
(95% CI) for CVD mortality for women who had ≥ 8 μg/
dL (≥ 0.384 μmol/L) versus the < 8 μg/dL (< 0.38 μmol/L)
blood lead concentrations was not significant; 1.78(95%
CI, 0.92–3.45), p = 0.089, women in higher lead group
experienced 3 fold higher risk of mortality due to coronary
heart disease 3.08(95% CI, 1.23–7.70), p < 0.016. There
was no association of blood lead and mortality from
stroke, cancer and other causes (Table 5 and Figure 2).
Discussion
Blood lead was an important predictor of all cause mortal-
ity in this cohort of community dwelling older women.
Mortality was significantly higher in women with blood
lead concentrations ≥ 8 μg/dL as compared to those with
lower blood lead concentrations. Our results are consist-
ent with earlier studies based on occupational cohorts
[3,24-26] and the general population: NHANES II and III
[4-7]. To our knowledge, this is the first study to look at
the association between blood lead concentrations and
mortality in older women with median age of 71 years
(range 65–87).
Table 1: Comparison of participants' baseline characteristics between SOF and lead ancillary study.
Characteristics (N total = 9704) Lead cohort N = 533 SOF participants N = 9171 P value
Age (years), mean SD 70 ± 4 72 ± 5 < 0.001
Body mass index (kg/m2)), mean SD 27 ± 5 26 ± 4 0.147
Education (years), mean SD 12 ± 3 13 ± 3 0.135
Alcohol (drinks/wk), mean SD 1.9 ± 4 1.8 ± 4 0.737
Current smoker, n (%) 65 (12) 902 (10) 0.079
Hypertension, n (%) 153 (29) 3594 (39) < 0.001
Diabetes, n (%) 55 (10) 652 (7) 0.006
Current estrogen use, n (%) 67 (13) 1400 (15) 0.091
Walk for exercise (yes/no), n (%) 213 (40) 4653 (51) < 0.001
Total hip, bone density (g/cm2), mean SD 0.77 ± 0.13 0.76 ± 0.13 0.536
Table 2: Baseline characteristics in women in SOF lead ancillary study by blood lead concentrations
Characteristics by blood lead concentration < 8 μg/dL
(< 0.384 μmol/L)
N = 453
≥ 8 μg/dL
(≥ 0.384 μmol/L)
N = 79
P value
All cause mortality, n (col %) 96 (21) 27 (34) 0.011
Age (years), mean ± SD 70 ± 4 70 ± 5 0.196
Body mass index (kg/m2)), mean ± SD 27 ± 5 26 ± 4 0.075
Education (years), mean ± SD 12 ± 3 13 ± 3 0.415
Alcohol (drinks/wk), mean ± SD 1.5 ± 3 2.9 ± 5 0.003
Current smoker, n (%) 46 (10) 20 (25) 0.001
Hypertension, n (%) 128 (28) 25 (32) 0.539
Diabetes, n (%) 48 (11) 7 (9) 0.644
Current estrogen use, n (%) 60 (13) 7 (9) 0.281
Walk for exercise (yes/no), n (%) 183 (40) 30 (38) 0.696
Total hip, bone density (g/cm2), mean ± SD 0.77 ± 0.13 0.72 ± 0.12 < 0.006Environmental Health 2009, 8:15 http://www.ehjournal.net/content/8/1/15
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Despite declines in blood lead concentrations during the
past 30 years, environmental lead exposure continues to
be a public health concern [2]. The use of organic lead as
gasoline additive, initiated during the 1920s, was phased
out in the US since 1976. Once released as combustion
exhaust, particulate lead persists in air, water, and soil.
Mean blood lead concentrations in the U.S. population in
the NHANES III Phase 2 collected during 1991 to 1994
ages 20 to 49 years were 2.1 μg/dL[1]. The mean blood
lead concentration for ages > 1 year has declined further
to 1.45 μg/dL(0.07 μmol/L) as reported from the most
recent survey (NHANES IV, 2001–2002)[27].
The skeleton is repository for 95% of absorbed lead and
can serve as an endogenous source for many years after
exposure. Lead may be mobilized from skeleton during
conditions of high bone turn over, such as pregnancy, lac-
tation, menopause and aging [28]. A 25% adjusted
increase in median blood lead concentration was reported
for post menopausal women, compared to premenopau-
sal women in NHANES II [29]. Furthermore in NHANES
III, blood lead concentrations were highest in ages 70
years and older [3.4 μg/dL,(0.16 μmol/L) ] [27].
A multitargeted toxicant, lead effects cardiovascular, renal
and nervous systems and may contribute to morbidity
and mortality through its adverse impacts on these sys-
tems. The increased cardiovascular mortality risk may
reflect an effect on sub-clinical risk factors for disease. The
evidence for this association is supportive [27]. As part of
NHANES III, an increased risk of peripheral arterial dis-
ease, hypertension and renal dysfunction was observed in
populations with an average blood lead concentration of
2  μg/dL (0.10 μmol/L) [2,14,27,30]. For example, the
odds ratio of diastolic hypertension was 8.1 comparing
women with a blood lead concentration of 4.0–31.1 μg/
dL (0.19–1.5 μmol/L) to women with lower blood lead
concentrations of 0.5–1.6 μg/dL(0.02–0.08  μmol/L).
Table 3: Baseline characteristics in women in SOF lead ancillary study by survival/mortality status.
Characteristic Died N = 123 Survived N = 410 P value
Age (years), mean ± SD 72 ± 5 70 ± 4 0.001
Education (years), mean ± SD 12 ± 3 12 ± 3 0.811
Body mass index(kg/m2)), mean ± SD 26 ± 5 27 ± 5 0.164
Alcohol (drinks/wk), mean ± SD 1.9 ± 5 1.8 ± 4 0.840
Current smoker, n (%) 25 (20) 41(10) 0.002
Hypertension, n (%) 47 (39) 106 (26) 0.007
Diabetes, n (%) 15 (12) 40 (10) 0.435
Current estrogen use, n (%) 12 (10) 55 (13) 0.283
Walk for exercise (yes/no), n (%) 41 (33) 172 (42) 0.087
Total hip, bone density (g/cm2), mean ± SD 0.71 ± 0.13 0.77 ± 0.13 < 0.001
All cause death, B-Pb (μg/dL) [μmol/L], mean ± SD 5.56 ± 3 [0.27 ± 0.14] 5.17 ± 2 [0.25 ± 0.1] 0.093
CVD death, B-Pb (μg/dL), [μmol/L], mean ± SD 5.81 ± 3 [0.28 ± 0.14 ] 5.19 ± 3 [0.25 ± 0.14] 0.059
CHD death, B-Pb (μg/dL), [μmol/L], mean ± SD 5.61 ± 2 [0.27 ± 0.1] 5.19 ± 2 [0.25 ± 0.1] 0.373
Stroke death, B-Pb (μg/dL), [μmol/L], mean ± SD 6.33 ± 3 [0.30 ± 0.14] 5.21 ± 2 [0.25 ± 0.1] 0.028
Cancer death, B-Pb (μg/dL), [μmol/L], mean ± SD 5.34 ± 2 [0.26 ± 0.1] 5.25 ± 2 [0.25 ± 0.1] 0.812
Other death, B-Pb (μg/dL), [μmol/L], mean ± SD 5.39 ± 4 [0.26 ± 0.19] 5.25 ± 2 [0.25 ± 0.1] 0.745
*B-Pb: blood lead concentration
Table 4: Multivariable model of all cause mortality by blood lead concentrations
Variable name Hazard Ratio 95% confidence interval p-value
Lead ≥ 8 μg/dL (≥ 0.384 μmol/L) 1.78 1.16, 2.73 0.008
Age increase per 5 years 1.62 1.36, 1.92 < 0.001
Clinic 1.56 1.06, 2.30 0.024
Body mass index(kg/m2)) 0.98 0.94, 1.02 0.239
Education (years) 0.98 0.92, 1.05 0.620
Alcohol (drinks/wk) 0.99 0.95, 1.04 0.814
Current smoker 1.84 1.18, 2.88 0.008
Hypertension 1.73 1.20, 2.49 0.003
Diabetes 1.11 0.83, 1.49 0.468
Current estrogen use 0.75 0.42, 1.38 0.363
Walk for exercise 0.70 0.48, 1.02 0.066
Total hip, bone density (g/cm2) 0.05 0.01, 0.19 0.001Environmental Health 2009, 8:15 http://www.ehjournal.net/content/8/1/15
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Other analyses support an association between blood lead
and renal function impairment [14,31,32], and increased
blood pressure [33,34], a biologically plausible relation-
ship [35].
Lead contributes to nephrotoxicity, even at blood concen-
tration below 5 ug/dL (0.24 μmol/L) [32]. Increase in
blood pressure and an association with renal damage
have also been observed after lead exposure in rodent
models [36,37]. Alterations in signal transduction that
involve renal pathways (eg, angiotensin and vasopressin)
were reported in rat models [38-40]. Other mechanisms
by which lead may increase cardiovascular risk include
effects on neuromuscular and neuro-humoral regulation
of vascular function, alteration in sodium transport, and
alterations in calcium regulation [7,11,27,30,41-47].
Blood lead was associated with almost three fold risk in
coronary heart disease (CHD) mortality (HR = 3.08) in
our study. Our results are consistent with findings in
which bone lead, a more accurate biomarker of chronic
lead exposure than blood lead was associated with
ischemic heart disease mortality [48]. A one standard
deviation increase in patella and tibia lead concentrations
was associated with greater risk for ischemic heart disease
(Hazard Ratio for patella lead = 1.29; 95% CI, 1.02–1.62).
Cumulative survival with blood lead concentrations < 8 μg/ dL (< 0.384 μmol/L), and ≥ 8 μg/dL (≥ 0.384 μmol/L) in  women in SOF Figure 1
Cumulative survival with blood lead concentrations < 
8 μg/dL (< 0.384 μmol/L), and ≥ 8 μg/dL (≥ 0.384 
μmol/L) in women in SOF. Cumulative survival associated 
with blood lead concentrations < 8 μg/dL (< 0.384 μmol/L), 
and ≥ 8 μg/dL (≥ 0.384 μmol/L), in women in SOF lead ancil-
lary study (Log rank test P < 0.007)
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Table 5: Hazards Ratio (HR) and 95% confidence interval of all cause mortality by blood lead concentrations
Cause of death Deaths Blood lead concentration (μg/dL) [μmol/L] Pvalue
(< 8) [< 0.384 ] (≥ 8) [≥ 0.384 ]
All cause death, n (Col %) 123 96 (21%) 27 (34%) 0.018*
Age, clinic adjusted 1.0 1.73 (1.12, 2.68) 0.014
Multivariate adjusted a 1.0 1.59 (1.02, 2.49) 0.041
Cardiovascular disease b, n(%) 54 41(9) 13 (16) 0.044*
Age, clinic adjusted 1.0 1.90 (1.00, 3.63) 0.054
Multivariate adjusted c 1.0 1.78 (0.92, 3.45) 0.089
Coronary heart disease d, n (%) 23 15 (4) 8 (11) 0.006*
Age, clinic adjusted 1.0 3.54 (1.48, 8.45) 0.004
Multivariate adjusted e 1.0 3.08 (1.23, 7.70) 0.016
Stroke f, n(%) 21 17 (4) 4 (5) 0.578*
Age, clinic adjusted 1.0 1.16 (0.34, 4.00) 0.816
Multivariate adjusted g 1.0 1.13 (0.34, 3.81) 0.840
Cancer h, n(%) 38 30 (7) 8 (10) 0.262*
Age, clinic adjusted 1.0 1.70 (0.77, 3.75) 0.185
Multivariate adjusted i 1.0 1.64 (0.73, 3.71) 0.231
All other deaths j, n(%) 31 25 (7) 6 (10) 0.289*
Age, clinic adjusted 1.0 1.51 (0.61, 3.72) 0.370
Multivariate adjusted k 1.0 1.22 (0.48, 3.10) 0.673
*Chi -square p-value only for percentage of deaths in two blood lead strata, the rest are hazards ratio p values.
a,c,e,g,i,k The multivariate model included the following: age, clinic, BMI, education, smoking, alcohol intake, estrogen use, hypertension, walking for 
exercise, diabetes, and total hip BMD.
b ICD9 Code: All deaths due to CVD, including all diseases of circulatory system except those involving veins and lymphatics: 425,429.2, 440–
444,428,401–404,410–414,430–438, and 798.
d ICD9 Code: deaths due to coronary heart disease: 410–414.
f ICD9 Code: Deaths due to stroke: 430–438.
h ICD9 Code: Deaths due to cancer: 140–239.
j ICD9 Code: All other deaths: Non CVD and non cancer deathsEnvironmental Health 2009, 8:15 http://www.ehjournal.net/content/8/1/15
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The pathogenesis of CHD is multifactorial; lead may be
one of the mediators by two causal pathways; i.e., media-
tion through higher blood pressure [8] and by atherogenic
process [49]. Lead-related atherosclerosis could be
explained by several mechanisms, impairment of renal
function [32], induction of oxidative stress [50] and
endothelial dysfunction [50].
Previous studies have linked lead as low as 3.62 μg/dL
(0.17 μmol/L)with an increased risk of stroke mortality
[7,8]. In our study, we found no significant association
with stroke, although the mean lead concentration in par-
ticipants who died due to stroke was 22% higher as com-
pared to the rest of the cohort (6.33 ug/dL vs. 5.21 ug/dL,
p < 0.028)(0.30 vs.0.25 μmol/L)perhaps reflecting the
small number of stroke deaths in this cohort (Table 3).
Lead is a toxic metal and categorized as probably carcino-
genic to humans (Group 2A IARC 2004) [51 Monograph].
Associations between occupational lead exposure and
cancers of brain, stomach, kidney and lung have been
reported [52-54]. However among non occupational
cohorts, there has been inconsistent evidence of an asso-
ciation between blood lead and cancer [5]. Individuals
with mean blood lead concentrations 10–19 μg/dL (0.48–
0.91 μmol/L) in the NHANES II cohort (1976–1980) did
not have increased risk of cancer mortality, when com-
pared to those with blood lead concentrations < 10 μg/dL
(0.48 μmol/L).
Our results are consistent with this observation as the
median value in the "≥ 8 μg/dL" lead group was 9 μg/dL
(0.43 μmol/L). A higher risk of cancer deaths was only
observed in with blood lead concentration > 20 μg/
dL(0.96 μmol/L) [4]. Similarly, individuals with blood
lead concentrations ≥ 3.62 μg/dL (0.17 μmol/L) in the
NHANES III (1988–1994) did not have increased risk of
cancer mortality when compared to those with < 1.94 μg/
dL(0.09 μmol/L) [7]. In contrast, another analysis from
the same population survey reported 44% increased risk
of cancer death at blood lead concentrations ≥ 5 μg/dL
(0.24 μmol/L) when compared to those with < 5 μg/dL
[6].
Bone loss accelerates after menopause and bone deminer-
alization may release bone lead into circulation [28].
Inverse association has been reported between mortality,
(predominantly stroke deaths) and bone density [55]. In
our study women with ≥ 8 μg/dL (≥ 0.384 μmol/L) blood
lead had 8% lower total hip bone mineral density at base-
line as compared to women with lower lead concentra-
tions. We also observed that women who died had 7%
higher blood lead concentration than survivors. In
another analysis in older women, each SD increase in
BMD loss at the hip was associated with a 1.3-fold
increase in total mortality, adjusted for age, baseline
BMD, diabetes, hypertension, incident fractures, smoking,
physical activity, health status, weight loss, and calcium
use. In particular, hip BMD loss was associated with
increased mortality from coronary heart disease (relative
hazard [RH] = 1.3 per SD; 95% CI, 1.0–1.8) [56].
Alternatively, osteoporosis and atherosclerosis may result
from elevated concentrations of homocysteine, an amino
acid whose normal metabolism depends on folate and
vitamin B12 as cofactors. Lead and homocysteine both are
associated with cardiovascular disease and cognitive dys-
function[57]. In subjects 50–70 years of age, blood lead
and homocysteine concentrations were correlated (Pear-
son's r = 0.27, p < 0.01), homocysteine concentration
increased 0.35 μmol/L per 1.0 μg/dL (0.05 μmol/L)
increase in blood lead (p < 0.01). Homocysteine is an
example of plausible mechanism that may mediate the
affect of lead on the cardiovascular [58] and central nerv-
ous systems [59]. Taken together, more research is clearly
needed to further our understanding of the mechanism of
lead toxicity and these multisystem outcomes.
Compared to the rest of SOF participants, the lead study
cohort was of comparatively younger age, and had lower
proportion with hypertension [60]. The proportion of
women with type 2 diabetes was higher in the lead cohort,
we adjusted for diabetes in secondary analysis and the
association of lead, and mortality remained significant.
The number ofwomen who are older and atrisk is grow-
Adjusted hazards ratios and 95% confidence interval of mor- tality in SOF participants with blood lead concentrations ≥ 8  μg/dL (≥ 0.384 μmol/L) Figure 2
Adjusted hazards ratios and 95% confidence interval 
of mortality in SOF participants with blood lead con-
centrations ≥ 8 μg/dL (≥ 0.384 μmol/L). Adjusted hazard 
ratios and 95% confidence interval of all cause mortality and 
cause specific mortality in SOF lead ancillary study partici-
pants with blood lead concentrations ≥ 8 μg/dL (≥ 0.384 
μmol/L), compared to referent < 8 μg/dL (< 0.384 μmol/L),
All cause death
CVD death
CHD death
Stroke 
Cancer
All other deaths
Hazard RatioEnvironmental Health 2009, 8:15 http://www.ehjournal.net/content/8/1/15
Page 8 of 10
(page number not for citation purposes)
ing. Cardiovascular disease is the leading cause of mortal-
ity worldwide [61] and in the United States [8]. It kills
nearlyhalf a million women in the United States every
year, more than the nextfivecauses of death combined and
nearly twice as many as all forms of cancer, including
breast cancer [62]. Environmental toxicants such as lead
may explain part of the burden of CVD.
There are several strengths to our study: our follow up was
more than 95% complete and we adjudicated all mortal-
ity events. We followed women for more than12 years
after the blood lead measures were obtained. We control-
led for a number of covariates and cardiovascular risk fac-
tors. However, this study has several limitations;
participation was limited to older Caucasian women, and
the findings may not apply to men or nonwhite women.
We did not determine co-contaminants such as cadmium
that might be associated with cardiovascular disease
through its known effects on kidney function [63,64].
There are factors that differ by lead concentrations and we
could not measure may have confounded our results. For
example we had no measure of renal function, homo-
cysteine or lipid concentrations and thus we could not
examine whether these measures influenced the associa-
tion between lead and mortality. We relied on death cer-
tificates and discharge summaries were only available for
33% of participants which may result in some misclassifi-
cation of cause of death [65]. Use of death certificates may
be problematic for assigning a single cause of death, espe-
cially among the oldest women who often have multiple
medical problems.
Conclusion
Our study extends the findings of higher mortality associ-
ated with blood lead concentrations from NHANES III
surveys to community dwelling older women. An
increased mortality risk, especially coronary heart disease
was found at blood lead concentrations ≥ 8 μg/dL (0.384
μmol/L). Our results add to the existing evidence of
adverse affects of lead on health as seen in an older cohort
who experienced greater historic environmental lead
exposure.
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